NeuExcell Therapeutics is a gene therapy company focusing on neurodegenerative diseases. Our vision is to restore health and improve the quality of life for millions of patients worldwide suffering from neurodegenerative diseases and CNS injuries. NeuExcell’s foundation is based on Professor Gong Chen’s scientific discovery of in vivo astrocyte-to-neuron (AtN) conversion using gene therapy. NeuExcell’s disruptive AtN technology has the potential to regenerate neuronal tissue in a damaged area caused by a wide variety of neurodegenerative conditions such as Stroke, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Traumatic Brain Injury, Spinal Cord Injury, Ophthalmic Diseases and Glioma.
NeuExcell's core technology achieves the therapeutic effect of neuroregeneration and repair through in situ astrocyte to neuron (AtN) conversion.
NeuExcell's in situ neuroregeneration technology platform, which uses endogenous glial cells to regenerate neurons in vivo, is suitable for the treatment of many major neurological diseases, including stroke, Huntington's disease, ALS, Alzheimer's disease, Parkinson's disease, traumatic brain injury, spinal cord injury, epilepsy, Ophthalmic diseases, and glioma.
“ NeuExcell has assembled a strong and experienced leadership team. Each team member brings decades of experience in gene therapy, neuroscience, biotech and pharma industry. The team is leading NeuExcell to drive the technology to clinic in several programs on a steady pace. ”